BR112021024999A2 - Inibidores de prmt5 - Google Patents

Inibidores de prmt5

Info

Publication number
BR112021024999A2
BR112021024999A2 BR112021024999A BR112021024999A BR112021024999A2 BR 112021024999 A2 BR112021024999 A2 BR 112021024999A2 BR 112021024999 A BR112021024999 A BR 112021024999A BR 112021024999 A BR112021024999 A BR 112021024999A BR 112021024999 A2 BR112021024999 A2 BR 112021024999A2
Authority
BR
Brazil
Prior art keywords
prmt5
overexpression
disorders
prmt5 inhibitors
relates
Prior art date
Application number
BR112021024999A
Other languages
English (en)
Inventor
Prabhakar Kulkarni Chaitanya
Sanjay Pawar Chetan
Raychand Lagad Dipak
Bhausaheb Gudade Ganesh
Bhaskar Tryambake Mahadeo
Dattatraya Sindkhedkar Milind
Sreedharan Nair Prathap
Kumar Kamboj Rajender
P Palle Venkata
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112021024999A2 publication Critical patent/BR112021024999A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

inibidores de prmt5. a invenção se refere a análogos de nucleosídeos substituídos de fórmula (i), seus sais e composições farmacêuticas farmaceuticamente aceitáveis, para o tratamento de doenças, distúrbios ou condições associadas à superexpressão da enzima prmt5. a invenção também se refere a métodos de tratamento de doenças, distúrbios ou condições associadas à superexpressão da enzima prmt5.
BR112021024999A 2019-06-10 2020-06-09 Inibidores de prmt5 BR112021024999A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921022972 2019-06-10
IN201921022971 2019-06-10
PCT/IB2020/055401 WO2020250123A1 (en) 2019-06-10 2020-06-09 Prmt5 inhibitors

Publications (1)

Publication Number Publication Date
BR112021024999A2 true BR112021024999A2 (pt) 2022-01-25

Family

ID=71670318

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024999A BR112021024999A2 (pt) 2019-06-10 2020-06-09 Inibidores de prmt5

Country Status (27)

Country Link
US (1) US20220315589A1 (pt)
EP (1) EP3980417B1 (pt)
JP (1) JP2022536337A (pt)
KR (1) KR20220019781A (pt)
CN (1) CN114026094B (pt)
AU (1) AU2020293021A1 (pt)
BR (1) BR112021024999A2 (pt)
CA (1) CA3141748A1 (pt)
CL (1) CL2021003292A1 (pt)
CO (1) CO2022000061A2 (pt)
CR (1) CR20220010A (pt)
DK (1) DK3980417T3 (pt)
EC (1) ECSP22001370A (pt)
ES (1) ES2967457T3 (pt)
FI (1) FI3980417T3 (pt)
HR (1) HRP20231673T1 (pt)
HU (1) HUE064493T2 (pt)
IL (1) IL288401A (pt)
LT (1) LT3980417T (pt)
MX (1) MX2021015262A (pt)
PE (1) PE20230245A1 (pt)
PL (1) PL3980417T3 (pt)
PT (1) PT3980417T (pt)
RS (1) RS64972B1 (pt)
SI (1) SI3980417T1 (pt)
WO (1) WO2020250123A1 (pt)
ZA (1) ZA202109573B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271540A1 (en) * 2021-06-21 2022-12-29 Mayo Foundation For Medical Education And Research Inhibitors of dot1l
WO2023278564A1 (en) * 2021-07-02 2023-01-05 Mirati Therapeutics, Inc. Aminopyridine-based mta-cooperative prmt5 inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
KR101198582B1 (ko) 2007-12-11 2012-11-06 에프. 호프만-라 로슈 아게 스테아로일-ｃｏａ 불포화화 효소의 억제제
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
CN102272105B (zh) 2008-11-14 2016-09-14 梅瑞尔公司 对映异构富集的芳基并唑-2-基氰基乙氨基杀寄生物化合物
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2013250726B2 (en) * 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
CA2899363A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
EP2975938A4 (en) 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
KR20160076519A (ko) 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102493854B1 (ko) 2014-06-25 2023-01-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 (s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염
EP3177288A4 (en) 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
EP3189048B1 (en) 2014-09-03 2021-03-17 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
TW201722957A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018167800A1 (en) 2017-03-13 2018-09-20 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof
US11459330B2 (en) * 2017-12-13 2022-10-04 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors

Also Published As

Publication number Publication date
CA3141748A1 (en) 2020-12-17
EP3980417B1 (en) 2023-09-27
PL3980417T3 (pl) 2024-03-18
MX2021015262A (es) 2022-04-06
CO2022000061A2 (es) 2022-04-08
EP3980417A1 (en) 2022-04-13
HRP20231673T1 (hr) 2024-03-15
US20220315589A1 (en) 2022-10-06
ES2967457T3 (es) 2024-04-30
CN114026094A (zh) 2022-02-08
IL288401A (en) 2022-01-01
KR20220019781A (ko) 2022-02-17
LT3980417T (lt) 2023-12-27
CL2021003292A1 (es) 2022-08-19
WO2020250123A1 (en) 2020-12-17
ZA202109573B (en) 2022-11-30
JP2022536337A (ja) 2022-08-15
HUE064493T2 (hu) 2024-03-28
CR20220010A (es) 2022-05-13
DK3980417T3 (en) 2023-12-18
SI3980417T1 (sl) 2024-02-29
AU2020293021A1 (en) 2021-12-23
CN114026094B (zh) 2024-06-25
ECSP22001370A (es) 2022-02-25
PT3980417T (pt) 2023-12-28
PE20230245A1 (es) 2023-02-07
RS64972B1 (sr) 2024-01-31
FI3980417T3 (fi) 2023-12-28

Similar Documents

Publication Publication Date Title
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
MX2023007192A (es) Inhibidores de prmt5.
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
CL2019002204A1 (es) Compuestos inhibidores del vih.
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
BR112021023824A2 (pt) Inibidor de proteína quinase dependente de dna
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
BR112022003408A2 (pt) Triazolopirimidinas como inibidores de a2a/a2b
BR112021021284A2 (pt) Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra
BR112019004254A2 (pt) inibidores da dopamina-b-hidroxilase penetrantes da barreira hematoencefálica
BR112021024999A2 (pt) Inibidores de prmt5
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
BR112017000132A2 (pt) composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k
BR112022010943A2 (pt) Análogos de nucleosídeos substituídos como inibidores de prmt5
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
BR112022005706A2 (pt) Inibidores de 1,6-naftiridina substituída de cdk5
BR112021026366A2 (pt) Compostos para tratamento de distúrbios oculares